Ce diaporama a bien été signalé.
Nous utilisons votre profil LinkedIn et vos données d’activité pour vous proposer des publicités personnalisées et pertinentes. Vous pouvez changer vos préférences de publicités à tout moment.

7 keys to open doors at Pfizer

54 vues

Publié le

7 keys to open doors at Pfizer. For sellers and marketers looking for account insights to help start new discussions with new decision makers at Pfizer.

Publié dans : Marketing
  • Login to see the comments

  • Soyez le premier à aimer ceci

7 keys to open doors at Pfizer

  1. 1.  The new initiative is focused on gene therapy. Pfizer operates a gene therapy research facility at the Sanford complex.  “The new facility will help advance Pfizer’s work in researching highly specialized, potentially one-time gene therapy treatments that use custom- made adeno-associated virus (AAV) vectors to deliver treatment effectively to patients” according to Pfizer. Pfizer to announce more jobs, investment at Sanford, NC plant
  2. 2.  Pfizer, the world’s largest drugmaker, plans to divest its off-patent drug business and combine it with generic-drug maker Mylan.  Under the agreement, which is structured as an all-stock deal, each Mylan share would be converted into one share of the new company.  Pfizer shareholders would own 57% of the combined new company and Mylan shareholders would own 43%, Mylan said. Pfizer will combine its off-patent drug business with Mylan
  3. 3.  Pfizer announced in mid-June that it would buy Array (ARRY) in a deal worth a reported $10.6 billion. Pfizer acquires Array BioPharma
  4. 4.  The FDA has approved Pfizer’s rituximab biosimilar, Ruxience (rituximab-pvvr), referencing Rituxan. The biosimilar was approved to treat non-Hodgkin lymphoma, chronic lymphocytic leukemia, and granulomatosis with polyangiitis and microscopic polyangiitis.  The fact that the biosimilar was not approved for all indications of its reference, a Pfizer representative told The Center for Biosimilars® in an email, is due to the fact that “Genentech has exclusivity for rituximab in certain indications. Pfizer has agreed to the terms of a global settlement,” but “specific terms and conditions of the settlement are confidential.” FDA Approves Pfizer's Rituximab Biosimilar, Ruxience
  5. 5.  Pfizer Inc said it acquired a 15 percent stake in Vivet Therapeutics, as well as an exclusive option to fully acquire it, a deal that will give it access to the French company’s experimental gene therapy for a rare genetic disorder called Wilson disease.  Pfizer has paid Vivet about $51 million upfront and may pay up to $635.8 million in clinical, regulatory milestone payments and to exercise the option to buy the whole company. Pfizer buys stake in French gene therapy firm Vivet
  6. 6.  The U.S. Food and Drug Administration approved Pfizer Inc’s oral drug, tafamidis, to treat a rare and fatal heart disease called transthyretin amyloid cardiomyopathy.  Pfizer, which has touted tafamidis as a potential blockbuster product, set a list price of $225,000 a year for the medicine, which would be sold under the brand name Vyndaqel. The U.S. Food and Drug Administration approved Pfizer Inc’s oral drug, tafamidis
  7. 7.  More than three years after snapping up Hospira, Pfizer has finally decided that some of its manufacturing facilities in India are beyond redemption.  The U.S. pharma will shut down its long-troubled injectables facility in Irungattukottai, India, as well as another site in Aurangabad, India, both of which were folded into Pfizer through the $15 billion acquisition of Hospira in 2015. Pfizer will shut down its injectables facility in Irungattukottai, India, as well as another site in Aurangabad, India
  8. 8. The Pfizer TURBO report has dozens of pages of customer insights compiled to help you sell and market more effectively. FORTUNE 500 TURBO REPORTS 844.DATABAHN 844.328.2224 ext. 707 info@databahn.com www.databahn.com We help sales reps and marketers eliminate costly research time and uncover new sales pipeline opportunities. Please visit www.databahn.com/page/turbo to download a TURBO Fortune 500 company profile report (PDF). We also build custom deep dive Fortune 1000 company profile reports. Please contact us if you need help.

×